+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
C

Actively Recruiting

Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.

Age: 18Years +All GendersPhase 3
107 locations
E

Actively Recruiting

Researchers are studying etrasimod to evaluate its safety, how it works in the body, and its effects for treating adolescents aged 12 to less than 18 years with moderately to severely active ulcerative colitis. This is a phase 2, open-label study focused on treatment in this younger population. Participants who complete the first year of treatment may continue in a long-term extension phase lasting up to 4 more years, totaling 5 years of study involvement. Participants will take etrasimod as a tablet or granules by mouth once daily for up to 52 weeks during the initial treatment phase. Those who finish this period can join the long-term extension to continue receiving the drug under study conditions. No placebo or comparison group is used, as all participants receive etrasimod. Throughout the study, researchers will monitor participants regularly to assess clinical remission using the Modified Mayo Score at weeks 12 and 52, along with endoscopic and symptomatic improvements. Blood samples will be taken at specified times to measure drug levels in the body. Safety will be tracked by recording any adverse events. Participants may be followed for up to 5 years from enrollment, including the long-term extension period.

Age: 12Years - 17YearsAll GendersPhase 2
47 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
56 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and tolerability of brivaracetam in children and adolescents with epilepsy, including those who participated in earlier studies or are newly enrolled in Japan with partial-onset seizures. The study also seeks to assess pharmacokinetic data in Japanese participants. The study is an open-label, single-arm, multicenter trial focusing on pediatric epilepsy treatment with brivaracetam. Participants will receive brivaracetam tablets or oral solution administered twice daily in two equal doses. Dosage varies based on weight up to 5 mgkgday for those weighing 11 to less than 20 kg, up to 4 mgkgday for those weighing 20 to less than 50 kg, and no more than 200 mgday. Directly enrolled participants in Japan will receive 1 to 4 mgkgday, not exceeding 200 mgday. The study includes long-term follow-up for up to 5 years. During the study, participants will be monitored for treatment-emergent adverse events, serious adverse events, and adverse events leading to discontinuation of the drug. Evaluations occur from Day 1 through safety visits over the 5-year period. Researchers will assess safety, tolerability, and pharmacokinetics. The total participation duration extends up to 5 years, with ongoing safety evaluations throughout this time.

Age: 1Month +All GendersPhase 3
36 locations
R

Actively Recruiting

This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.

Age: 18Years +All GendersPhase 3
285 locations
T

Actively Recruiting

Researchers are evaluating the effects of mexiletine hydrochloride in men with spinal and bulbar muscular atrophy SBMA, a condition that causes muscle weakness. This clinical trial aims to determine if mexiletine hydrochloride can improve motor function as measured by the ALS Functional Rating Scale-Revised ALSFRS-R score. The study is designed as a randomized, placebo-controlled, double-blind trial to assess both the efficacy and safety of the drug. Participants will be randomly assigned to receive either mexiletine hydrochloride or a placebo. The active treatment involves taking 300 mg of mexiletine hydrochloride orally, divided into three doses after meals each day for 12 weeks. The placebo group will follow the same schedule with an inactive substance. Hospital visits for evaluation will occur every four weeks during the treatment period. During the study, participants will undergo regular assessments including ALSFRS-R scoring at 4 weeks and up to 12 weeks, as well as other tests such as grip strength, tongue pressure, timed walking tests, and respiratory function tests measuring forced vital capacity and peak expiratory flow. These evaluations will help measure motor function and respiratory health. Safety and adherence will be closely monitored throughout the 3-month treatment period.

Age: 18Years - 80YearsMALEPhase 2Phase 3
5 locations
I

Actively Recruiting

This research focuses on improving the safety and quality of tracheal intubation practices in pediatric intensive care units PICUs, cardiac ICUs CICUs, neonatal ICUs NICUs, emergency departments EDs, and delivery rooms DRs. It addresses the risks associated with advanced airway interventions in critically ill children, aiming to reduce life- and health-threatening complications during these high-risk procedures. The study is part of a multi-center quality improvement collaborative called NEAR4KIDS. The study collects detailed baseline data on airway management practices across multiple centers to benchmark and compare care. This observational approach helps identify current practices and monitor changes over time. The goal is to use this data to support quality improvement interventions that enhance safety and reduce complications related to tracheal intubation and related airway management techniques. Participants include patients of all ages undergoing advanced airway events in PICU, CICU, NICU, DR, and ED settings. Researchers will track the occurrence of tracheal intubation-associated events TIAEs throughout each patients hospital stay, typically averaging about four weeks. Data collection involves monitoring airway procedures and outcomes to assess changes in complication rates and the overall effectiveness of quality improvement efforts.

All AgesAll Genders
87 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-90301900 NBTXR3 activated by radiotherapy with or without cetuximab compared to radiotherapy with or without cetuximab alone in elderly participants with locally advanced head and neck squamous cell carcinoma LA-HNSCC who are not eligible for platinum-based chemotherapy. This Phase 3 pivotal trial includes participants aged 60 and older who have not received prior treatment and meet specific clinical and health criteria. Participants are randomly assigned to one of two groups one group receives JNJ-90301900 NBTXR3 as an intratumoral or intranodal injection at a dose of 33% of the gross tumor volume, activated by investigators choice of radiotherapy alone or combined with cetuximab. The other group receives radiotherapy alone or radiotherapy combined with cetuximab. Radiotherapy is delivered as intensity-modulated radiation therapy IMRT at 70 Gray in 35 fractions over 7 weeks. During the study, participants undergo assessments to monitor progression-free survival, overall survival, local and distant cancer control, quality of life using specific questionnaires, safety through adverse event monitoring, and response rates. These evaluations occur up to 48 months following the first randomized participant. The trial is open-label with no masking, and participation lasts until study completion, with safety and efficacy continuously monitored.

Age: 60Years +All GendersPhase 3
196 locations
C

Actively Recruiting

This clinical trial is studying adults who have experienced a small ischemic stroke, also known as lacunar stroke. It aims to determine if a combination of antiplatelet drugs dual antiplatelet therapy works as well as the standard treatment with intravenous tissue plasminogen activator rt-PA. Researchers also want to see if the combination reduces bleeding complications compared to rt-PA. Participants will be randomly assigned to receive either the dual antiplatelet therapy, which includes aspirin 200 mg and clopidogrel 300 mg, or intravenous rt-PA at a low dose of 0.6 mgkg alteplase, which is approved in Japan. The study follows a parallel design and is conducted at multiple centers. Treatment is given during the hyperacute phase within 4.5 hours of stroke onset. During the study, participants will be monitored for neurological status at 3 months after stroke through in-person visits, phone calls, or mail. Researchers will measure outcomes such as excellent recovery at 3 months, infarct growth, early neurological changes, stroke recurrence, and cost effectiveness. The total study period extends through March 2029, with primary outcome assessment at 3 months post-stroke.

Age: 18Years +All GendersPhase 4
29 locations

1-10 of 18

1